
Sign up to save your podcasts
Or
How do STAMP inhibitors differ from ATP-competitive tyrosine kinase inhibitors (TKIs) when treating chronic myeloid leukemia (CML)?
Credit available for this activity expires: 03/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm?ecd=bdc_podcast_libsyn_mscpedu
4.2
2222 ratings
How do STAMP inhibitors differ from ATP-competitive tyrosine kinase inhibitors (TKIs) when treating chronic myeloid leukemia (CML)?
Credit available for this activity expires: 03/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm?ecd=bdc_podcast_libsyn_mscpedu
129 Listeners
42 Listeners
13 Listeners
313 Listeners
853 Listeners
488 Listeners
695 Listeners
16 Listeners
264 Listeners
255 Listeners
3,317 Listeners
89 Listeners
1,071 Listeners
169 Listeners
506 Listeners
317 Listeners
58 Listeners
9 Listeners
239 Listeners
365 Listeners